ecancermedicalscienceIntense Chemo Best for Aggressive LymphomaMedscapeNovember 29, 2011 — Adding rituximab to a dose-intensive immunochemotherapy regimen significantly improves survival in young patients with diffuse large B cell lymphoma with low-i…
Bristol-Myers Squibb (BMY) Breaks Through Resistance at $31.30 – Financial News Network Online
Bristol-Myers Squibb (BMY) Breaks Through Resistance at $31.30Financial News Network OnlineThe Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant reject…
Man's plea to save his wife's life – Grantham Today
Man's plea to save his wife's lifeGrantham TodayHusband Paul Jenkins from Hertfordshire is urging people to join the stem cell transplant register after his wife was diagnosed with a type of blood cancer. Gilly Jenkins was diagnosed with Hodgki…
Stem cell transplant breakthrough 'may offer hope regarding epilepsy' – Epilepsy Research UK
Epilepsy Research UKStem cell transplant breakthrough 'may offer hope regarding epilepsy'Epilepsy Research UKA new breakthrough regarding stem cell transplants could offer hope to those who are affected by epilepsy. The neurological condition i…
US Oncology Research Affiliated Investigators Participated in Studies that … – MarketWatch (press release)
US Oncology Research Affiliated Investigators Participated in Studies that …MarketWatch (press release)"When we presented our data with the Syk inhibitor fostamatinib at the ASH plenary session in 2008, B Cell Receptor signaling inhibitors were …
Vitro Biopharma Introduces New Products for Personalized Cellular Medicine – MarketWatch (press release)
Vitro Biopharma Introduces New Products for Personalized Cellular MedicineMarketWatch (press release)… to study potential treatment of various conditions including, Type I & II diabetes, Parkinson's disease, organ transplant rejection, osteoa…
Talon Therapeutics Announces First Patient Enrolled in the Phase 3 OPTIMAL>60 … – MarketWatch (press release)
Talon Therapeutics Announces First Patient Enrolled in the Phase 3 OPTIMAL>60 …MarketWatch (press release)The title of the DSHNHL study is "Improvement of outcome and reduction in toxicity in elderly patients with CD20+ aggressive B-cell lymp…
Crucial part of nervous system linked to increased risk of death from heart … – News-Medical.net
Crucial part of nervous system linked to increased risk of death from heart …News-Medical.netA loss of vagal control is a major risk factor in human cardiovascular diseases such as heart failure and hypertension. Vagal information to the heart is tra…
Alnylam Completes Enrollment in Phase IIb Study of ALN-RSV01, an RNAi … – MarketWatch (press release)
Alnylam Completes Enrollment in Phase IIb Study of ALN-RSV01, an RNAi …MarketWatch (press release)… in the US RSV infection in lung transplant patients represents an important unmet medical need; the condition is associated with significant morbidi…
Updated Results From Gentium's Treatment IND for Defibrotide to be Presented … – MarketWatch (press release)
Updated Results From Gentium's Treatment IND for Defibrotide to be Presented …MarketWatch (press release)"Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients: Early Int…